Current Hepatitis Reports

, Volume 12, Issue 3, pp 157–164

Tertiary Prevention of HBV-related HCC in Asia

  • Grace Lai-Hung Wong
  • Ching-Ning Chong
  • Vincent Wai-Sun Wong
Global Perspectives: Taiwan and Asia (ML Yu and RN Chien, Section Editors)

Abstract

Chronic hepatitis B is the leading cause of hepatocellular carcinoma (HCC) in Asia. Despite liver resection or local ablation therapy, up to 70 % of patients will have HCC recurrence. While early HCC recurrence within 2 years of index treatment is mainly associated with tumor characteristics such as vascular invasion and tumor number, late recurrence arises due to field effect and is associated with high hepatitis B virus DNA level and hepatic necroinflammation. Although current data suggest that antiviral therapy can reduce the risk of cirrhosis and incident HCC, its role in preventing HCC recurrence after curative treatment remains controversial. In recent years, knowledge on the signaling pathways of HCC has led to exciting development in targeted therapy, with sorafenib being the first to be registered for the treatment of advanced HCC. Further studies are needed to clarify the role of targeted therapy in the adjuvant setting to prevent HCC recurrence.

Keywords

Hepatitis B HBV DNA Hepatocellular carcinoma Cirrhosis Lamivudine Entecavir Tenofovir Interferon Sorafenib Sirolimus 

Abbreviations

HBeAg

hepatitis B e antigen

HBsAg

hepatitis B surface antigen

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

mTOR

mammalian target of rapamycin

NA

nucleos(t)ide analog

OLT

orthotopic liver transplantation

RFA

radiofrequency ablation

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Grace Lai-Hung Wong
    • 1
    • 2
  • Ching-Ning Chong
    • 1
    • 3
  • Vincent Wai-Sun Wong
    • 1
    • 2
  1. 1.Institute of Digestive DiseaseThe Chinese University of Hong KongHong KongChina
  2. 2.Department of Medicine and TherapeuticsThe Chinese University of Hong KongShatinHong Kong
  3. 3.Department of SurgeryThe Chinese University of Hong KongHong KongChina

Personalised recommendations